A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.
CRISPR Therapeutics
Seattle Children's Hospital
Seattle Children's Hospital
National Institutes of Health Clinical Center (CC)
Multitude Therapeutics Inc.